Influenza virosomes as adjuvants in cancer immunotherapy

Liposome Technology: Third Edition

Volumn 2, Issue , 2016, Pages 221-231

  Schumacher, Reto ^a   Spagnoli, Giulio C ^a   Adamina, Michel ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748510115     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (10)

1. Glück R, Metcalfe IC. New technology platforms in the development of vaccines for the future. Vaccine 2002; 20: B10.
2. Singh M, O'Hagan D. Advances in vaccine adjuvants. Nature Biotechnol 1999; 17: 1075.
3. Raychaudhuri S, Rock KL. Fully mobilizing host defense: building better vaccines. Nat Biotechnol 1998; 16: 1025.
4. Seder RE, Hill AVS. Vaccines against intracellular infections requiring cellular immunity. Nature 2000; 406: 793.
5. Moingeon P, Haensler J, Lindberg A. Towards the rational design of Th1 adjuvants. Vaccine 2001; 19: 4363.
6. Schumacher R, Adamina A, Zurbriggen R, et al. Influenza virosomes enhance class I restricted CTL induction through CD4þ T cell activation. Vaccine 2004; 22: 714.
7. Skehel JJ, Schild GC. The polypeptide composition of influenza A viruses. Virology 1971; 44: 396.
8. Guesdon JL, Avrameas S. An immunoenzymatic method for measuring low concentrations of antigens by single radial diffusion. Immunochemistry 1974; 11: 595.
9. Filgueira L, Zuber M, Juretic A, et al. Differential effects of interleukin-2 and CD3 triggering on cytokine gene transcription and secretion in cultured tumor infiltrating lymphocytes. Cell Immunol 1993; 150: 205.
10. Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101(4): 746.